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david moher and colleagues introduce PRISMA, an update of the QUOROM guidelines 
for reporting systematic reviews and meta-analyses
generally poor; between one and 14 characteristics 
were adequately reported (mean 7.7, standard devia-
tion 2.7). A 1996 update of this study found little 
improvement.7
In 1996, to address the suboptimal reporting of 
meta-analyses, an international group developed a 
guidance called the QUOROM statement (QUality 
Of Reporting Of Meta-analyses), which focused on 
the reporting of meta-analyses of randomised control-
led trials.8 In this article, we summarise a revision 
of these guidelines, renamed PRISMA (Preferred 
Reporting Items for Systematic reviews and Meta-
Analyses), which have been updated to address sev-
eral conceptual and practical advances in the science 
of systematic reviews (see box).
terminology
The terminology used to describe a systematic review 
and meta-analysis has evolved over time. One reason 
for changing the name from QUOROM to PRISMA 
was the desire to encompass both systematic reviews 
Systematic reviews and meta-analyses have become 
increasingly important in health care. Clinicians read 
them to keep up to date with their specialty,1 2 and 
they are often used as a starting point for developing 
clinical practice guidelines. Granting agencies may 
require a systematic review to ensure there is justifica-
tion for further research,3 and some medical journals 
are moving in this direction.4 As with all research, the 
value of a systematic review depends on what was 
done, what was found, and the clarity of reporting. 
As with other publications, the reporting quality of 
systematic reviews varies, limiting readers’ ability to 
assess the strengths and weaknesses of those reviews.
Several early studies evaluated the quality of review 
reports. In 1987 Mulrow examined 50 review articles 
published in four leading medical journals in 1985 
and 1986 and found that none met all eight explicit 
scientific criteria, such as a quality assessment of 
included studies.5 In 1987 Sacks and colleagues evalu-
ated the adequacy of reporting of 83 meta-analyses 
on 23 characteristics in six domains.6 Reporting was 
Completing a systematic review is an iterative 
process
The conduct of a systematic review depends heavily 
on the scope and quality of included studies: 
thus systematic reviewers may need to modify 
their original review protocol during its conduct. 
Any systematic review reporting guideline should 
recommend that such changes can be reported 
and explained without suggesting that they are 
inappropriate. The PRISMA statement (items 5, 11, 
16, and 23) acknowledges this iterative process. 
Aside from Cochrane reviews, all of which should 
have a protocol, only about 10% of systematic 
reviewers report working from a protocol.9 Without 
a protocol that is publicly accessible, it is difficult 
to judge between appropriate and inappropriate 
modifications.
Conduct and reporting of research are distinct 
concepts
This distinction is, however, less straightforward 
for systematic reviews than for assessments of 
the reporting of an individual study, because the 
reporting and conduct of systematic reviews are, by 
nature, closely intertwined. For example, the failure 
of a systematic review to report the assessment of 
the risk of bias in included studies may be seen as a 
marker of poor conduct, given the importance of this 
activity in the systematic review process.10
Study-level versus outcome-level assessment of 
risk of bias
For studies included in a systematic review, a 
thorough assessment of the risk of bias requires 
both a study-level assessment (such as adequacy 
of allocation concealment) and, for some 
features, a newer approach called outcome-level 
assessment. An outcome-level assessment 
involves evaluating the reliability and validity 
of the data for each important outcome by 
determining the methods used to assess them in 
each individual study.11 The quality of evidence 
may differ across outcomes, even within a study, 
such as between a primary efficacy outcome, 
which is likely to be carefully and systematically 
measured, and the assessment of serious 
harms,12 which may rely on spontaneous reports 
by investigators. This information should be 
reported to allow an explicit assessment of the 
extent to which an estimate of effect is correct.11
Importance of reporting biases
Different types of reporting biases may hamper 
the conduct and interpretation of systematic 
reviews. Selective reporting of complete 
studies (such as publication bias),13 as well as 
the more recently empirically demonstrated 
“outcome reporting bias” within individual 
studies,14 15 should be considered by authors 
when conducting a systematic review and 
reporting its results. Although the implications 
of these biases on the conduct and reporting 
of systematic reviews themselves are unclear, 
some research has identified that selective 
outcome reporting may occur also in the 
context of systematic reviews.16
Conceptual issues in the evolution from QUOROM to PRISMA
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table 1 | Checklist of items to include when reporting a systematic review or meta-analysis
Section/topic Item No Checklist item
Reported on page 
No
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both
Abstract
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, 
data sources, study eligibility criteria, participants, interventions, study appraisal 
and synthesis methods, results, limitations, conclusions and implications of key 
findings, systematic review registration number
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS)
Methods
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (such as 
web address), and, if available, provide registration information including 
registration number
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report 
characteristics (such as years considered, language, publication status) used 
as criteria for eligibility, giving rationale
Information sources 7 Describe all information sources (such as databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched
Search 8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included 
in systematic review, and, if applicable, included in the meta-analysis)
Data collection process 10 Describe method of data extraction from reports (such as piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators
Data items 11 List and define all variables for which data were sought (such as PICOS, funding 
sources) and any assumptions and simplifications made
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (such as I2 statistic) for each meta-
analysis
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(such as publication bias, selective reporting within studies)
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram
Study characteristics 18 For each study, present characteristics for which data were extracted (such as 
study size, PICOS, follow-up period) and provide the citations
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome-level 
assessment (see item 12).
Results of individual studies 20 For all outcomes considered (benefits or harms), present for each study (a) 
simple summary data for each intervention group and (b) effect estimates and 
confidence intervals, ideally with a forest plot
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see item 15)
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup 
analyses, meta-regression) (see item 16)
Discussion
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (such as health care providers, 
users, and policy makers)
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at 
review level (such as incomplete retrieval of identified research, reporting 
bias)
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research
Funding
Funding 27 Describe sources of funding for the systematic review and other support (such 
as supply of data) and role of funders for the systematic review
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and meta-analyses. We have adopted the definitions 
used by the Cochrane Collaboration.17 A systematic 
review is a review of a clearly formulated question that 
uses systematic and explicit methods to identify, select, 
and critically appraise relevant research, and to collect 
and analyse data from the studies that are included 
in the review. Statistical methods (meta-analysis) may 
or may not be used to analyse and summarise the 
results of the included studies. Meta-analysis refers to 
the use of statistical techniques in a systematic review 
to integrate the results of included studies.
developing the prisma statement
A three-day meeting was held in Ottawa, Canada, 
in June 2005 with 29 participants, including review 
authors, methodologists, clinicians, medical editors, and 
a consumer. The objective of the Ottawa meeting was 
to revise and expand the QUOROM checklist and flow 
diagram as needed.
The executive committee completed the following 
tasks before the meeting: a systematic review of studies 
examining the quality of reporting of systematic reviews; 
a comprehensive literature search to identify methodo-
logical and other articles that might inform the meeting, 
especially in relation to modifying checklist items; and 
an international survey of review authors, consumers, 
and groups commissioning or using systematic reviews 
and meta-analyses (including the International Network 
of Agencies for Health Technology Assessment and the 
Guidelines International Network) to ascertain views of 
QUOROM, including the merits of the existing checklist 
items. The results of these activities were presented dur-
ing the meeting and are summarised on the PRISMA 
website, www.prisma-statement.org/.
Only items deemed essential were retained or added 
to the checklist. Some additional items are nevertheless 
desirable, and review authors should include these, if 
relevant.18 For example, it is useful to indicate whether 
the systematic review is an update of a previous review19 
and to describe any changes in procedures from those 
described in the original protocol.
Shortly after the meeting, a draft of the PRISMA 
checklist was circulated to the group, including those 
invited to the meeting but unable to attend. A dispo-
sition file was created containing comments and revi-
sions from each respondent, and the checklist was 
subsequently revised 11 times. The group approved the 
checklist, flow diagram, and this summary paper.
Although no direct evidence was found to support 
retaining or adding some items, evidence from other 
domains was believed to be relevant. For example, 
item 5 asks authors to provide registration information 
about the systematic review, including a registration 
number if available. Although systematic review regis-
tration is not yet widely available,20 21 the participating 
journals of the International Committee of Medical 
Journal Editors22 now require all clinical trials to be 
registered in an effort to increase transparency and 
accountability.23 Those aspects are also likely to ben-
efit systematic reviewers, possibly reducing the risk of 
an excessive number of reviews addressing the same 
question24 25 and providing greater transparency when 
updating systematic reviews.
the prisma statement
The PRISMA statement consists of a 27 item checklist 
(table1) and a four phase flow diagram (figure) (also 
available as extra items on bmj.com for researchers to 
download and re-use). The aim of the PRISMA state-
ment is to help authors improve the reporting of sys-
tematic reviews and meta-analyses. We have focused 
on randomised trials, but PRISMA can also be used as 
a basis for reporting systematic reviews of other types 
of research, particularly evaluations of interventions. 
PRISMA may also be useful for critical appraisal of 
published systematic reviews. However, the PRISMA 
checklist is not a quality assessment instrument to 
gauge the quality of a systematic review.
From QuoRoM to PRIsMa
The new PRISMA checklist differs in several respects 
from the QUOROM checklist, and table 2 lists the 
substantive specific changes. Generally, the PRISMA 
checklist “decouples” several items present in the 
QUOROM checklist and, where applicable, several 
checklist items are linked to improve consistency 
across the systematic review report.
The flow diagram has also been modified. Before 
including studies and providing reasons for excluding 
others, the review team must first search the litera-
ture. This search results in records. Once these records 
have been screened and eligibility criteria applied, a 
smaller number of articles will remain. The number 
of included articles might be smaller (or larger) than 
the number of studies, because articles may report on 
multiple studies and results from a particular study 
may be published in several articles. To capture this 
information, the PRISMA flow diagram now requests 
information on these phases of the review process.
endorsement
The PRISMA statement should replace the QUOROM 
statement for those journals that have endorsed 
Flow of information through the different phases of a 
systematic review
No of records identified
through database searching
No of additional records
identified through other sources
No of records after duplicates removed
No of studies included in qualitative synthesis
No of studies included in quantitative synthesis (meta-analysis)
Identification
Screening
Eligibility
Included
No of records screened No of records excluded
No of full-text articles
assessed for eligibility
No of full-text articles
excluded, with reasons
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tigate cost effectiveness,37 diagnostic38 or prognostic ques-
tions,39 genetic associations,40 and policy making.41 The 
general concepts and topics covered by PRISMA are 
relevant to any systematic review, not just those sum-
marising the benefits and harms of a healthcare interven-
tion. However, some modifications of the checklist items 
or flow diagram will be necessary in particular circum-
stances. For example, assessing the risk of bias is a key 
concept, but the items used to assess this in a diagnostic 
review are likely to focus on issues such as the spectrum 
of patients and the verification of disease status, which 
differ from reviews of interventions. The flow diagram 
will also need adjustments when reporting meta-analysis 
of individual patient data.42
We have developed an explanatory document to 
increase the usefulness of PRISMA.26 For each checklist 
item, this document contains an example of good report-
ing, a rationale for its inclusion, and supporting evidence, 
including references, whenever possible. We believe this 
document will also serve as a useful resource for those 
teaching systematic review methodology. We encourage 
journals to include reference to the explanatory docu-
ment in their instructions to authors.
Like any evidence based endeavour, PRISMA is 
a living document. To this end we invite readers to 
comment on the revised version, particularly the new 
checklist and flow diagram, through the PRISMA web-
site. We will use such information to inform PRISMA’s 
continued development.
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QUOROM. We hope that other journals will support 
PRISMA; they can do so by registering on the PRISMA 
website. To emphasise to authors and others the impor-
tance of transparent reporting of systematic reviews, we 
encourage supporting journals to reference the PRISMA 
statement and include the PRISMA web address in their 
instructions to authors. We also invite editorial organi-
sations to consider endorsing PRISMA and encourage 
authors to adhere to its principles.
the PRIsMa explanation and elaboration paper
In addition to the PRISMA statement, a supporting 
explanation and elaboration document has been pro-
duced26 following the style used for other reporting 
guidelines.27-29 The process of completing this document 
included developing a large database of exemplars to 
highlight how best to report each checklist item, and 
identifying a comprehensive evidence base to support 
the inclusion of each checklist item. The explanation and 
elaboration document was completed after several face 
to face meetings and numerous iterations among several 
meeting participants, after which it was shared with the 
whole group for additional revisions and final approval. 
Finally, the group formed a dissemination subcommittee 
to help disseminate and implement PRISMA.
discussion
The quality of reporting of systematic reviews is still 
not optimal.9 30-34 In a recent review of 300 systematic 
reviews, few authors reported assessing possible publica-
tion bias,9 even though there is overwhelming evidence 
for its existence13 and its impact on the results of system-
atic reviews.35 Even when the possibility of publication 
bias is assessed, there is no guarantee that systematic 
reviewers have assessed or interpreted it appropriately.36 
Although the absence of reporting such an assessment 
does not necessarily indicate that it was not done, report-
ing an assessment of possible publication bias is likely to 
be a marker of the thoroughness of the conduct of the 
systematic review.
Several approaches have been developed to conduct 
systematic reviews on a broader array of questions. For 
example, systematic reviews are now conducted to inves-
table 2 |Substantive specific changes between the QUOROM checklist and the PRISMA checklist (a tick indicates the presence of the topic in QUOROM or PRISMA)
Section/topic and item
QUOROM PRISMA Comment
Abstract √ √ QUOROM and PRISMA ask authors to report an abstract. However, PRISMA is not specific about format
Introduction:
 Objective √ This new item (4) addresses the explicit question the review addresses using the PICO reporting system (which describes the participants, 
interventions, comparisons, and outcome(s) of the systematic review), together with the specification of the type of study design (PICOS); 
the item is linked to items 6, 11, and 18 of the checklist
Methods:
 Protocol √ This new item (5) asks authors to report whether the review has a protocol and if so how it can be accessed
 Search √ √ Although reporting the search is present in both QUOROM and PRISMA checklists, PRISMA asks authors to provide a full description of at 
least one electronic search strategy (item 8). Without such information it is impossible to repeat the authors’ search
 Assessment of risk of bias 
in included studies
√ √ Renamed from “quality assessment” in QUOROM. This item (12) is linked to reporting this information in the results (item 19). The new 
concept of “outcome level” assessment has been introduced
 Assessment of risk of bias 
across studies
√ This new item (15) asks authors to describe any assessments of risk of bias in the review, such as selective reporting within the included 
studies. This item is linked to reporting this information in the results (item 22)
Discussion √ √ Although both QUOROM and PRISMA checklists address the discussion section, PRISMA devotes three items (24-26) to the discussion. In 
PRISMA the main types of limitations are explicitly stated and their discussion required
Funding √ This new item (27) asks authors to provide information on any sources of funding for the systematic review.
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